Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $232 from $225 and keeps an Overweight rating on the shares. Tenet delivered “another strong earnings report” and higher margins and improving free cash flow are supporting capital investment to add higher acuity service lines in the hospital segment and exceed targeted M&A in Ambulatory Surgical Centers, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA
- Morning Movers: UPS and PayPal jump following quarterly reports